To Terafl EKSTRATAB

General characteristics. Structure:

Active agents: paracetamol of 650 mg, chlorpheniramine maleate of 4 mg, Phenylephrinum hydrochloride of 10 mg

excipients: silicon dioxide colloid, quinolinic varnish yellow lactose, magnesium stearate, hydroxypropyl cellulose, croscarmellose sodium, starch corn, quinolinic yellow, titanium dioxide, methylparahydroxybenzoate, povidone, polyethyleneglycol 400, methyl cellulose

Pharmacological properties:

The combined drug; possesses the febrifugal, antiedematous, anesthetizing and antiallergic action.

Indications to use:

Symptomatic therapy of the infectious and inflammatory diseases (SARS, flu) which are followed by high temperature, fever, a headache, a rhinorrhea (cold), a nose congestion, sneezing and muscle pains.

Route of administration and doses:

Inside, on 1 tablet each 6 hours. To swallow a tablet entirely, without chewing, washing down with water. The maximum daily dose for zrosly - 6 tablets a day, for children over 12 years - 4 tablets a day. If relief of symptoms within 3 days after the beginning of administration of drug is not observed, it is necessary to see a doctor.

Features of use:

In order to avoid toxic damage of a liver administration of drug should not be combined using alcoholic beverages.

During treatment it is not recommended to drive the car or other mechanisms demanding concentration of attention and high speed of psychomotor reactions.

Side effects:

Allergic reactions (skin rash, itch, small tortoiseshell, Quincke's disease), drowsiness, nausea, epigastric pain, dryness in a mouth, a mydriasis, accommodation paresis, an ischuria, increase in intraocular pressure, редкот - anemia, thrombocytopenia, an agranulocytosis. Hyperexcitability, dizziness, increase in arterial pressure, backfilling disturbance.

At prolonged use in high doses - a hepatotoxic action, hemolitic anemia, aplastic anemia, a methemoglobinemia, a pancytopenia; nephrotoxicity (renal colic, glucosuria, intersticial nephrite, papillary necrosis).

Interaction with other medicines:

The risk of a hepatotoxic action of paracetamol increases at co-administration of barbiturates, dipheninum, carbamazepine, rifampicin, a zidovudine and other inductors of microsomal enzymes of a liver.

Strengthens effects of inhibitors of a monoaminooxidase (MAO), sedative medicines, ethanol. It is recommended to refrain from administration of drug at reception of MAO inhibitors. Ethanol strengthens sedative effect of antihistaminic medicines. Antidepressants, fenotiazinovy derivative, protivoparkinsonichesky and antipsychotic medicines increase risk of development of an ischuria, dryness in a mouth, a lock. Glucocorticosteroids increase risk of development of glaucoma.

Paracetamol reduces efficiency of uricosuric medicines.

Chlorphenaminum along with MAO inhibitors, furasolidone can lead to hypertensive crisis, excitement, a hyper pyrexia. Tricyclic antidepressants strengthen adrenomimetichesky action of Phenylephrinum, co-administration of a halothane increases risk of development of ventricular arrhythmia. Reduces hypotensive action of a guanetidin who, in turn, increases alpha адреностимулирующую activity of Phenylephrinum.

Contraindications:

Hypersensitivity to separate components of drug. Pregnancy, breastfeeding period. Children's age up to 12 years.

With care:

arterial hypertension, diabetes mellitus, closed-angle glaucoma, serious illness of a liver or kidneys, hyperplasia of a prostate, blood disease, deficit glyukozo-6-fosfatdegidrogenazy, thyrotoxicosis, bronchial asthma, HOBL (emphysema of lungs, chronic bronchitis).

Overdose:

Symptoms: nausea, vomiting, pains in epigastric area; hepatotoxic and nephrotoxic action, in hard cases develops a liver failure, encephalopathy and a coma.

Treatment: a gastric lavage, absorbent carbon in the first 6 h, introduction of donators of SH-group and predecessors of synthesis of glutathione - methionine in 8-9 h after overdose and N-Acetylcysteinum in 12 h.

Storage conditions:

To store at a temperature not above 25 °C, in the place, unavailable to children. Period of validity: 2 years. Not to use after the term noted by <EHR> on packaging.

Issue conditions:

Without recipe

Packaging:

On 10 tablets in the blister packaging together with the application instruction are enclosed in packaging from a cardboard. On 1 - 2 blister